tiprankstipranks
Advertisement
Advertisement
Edgewise Therapeutics price target raised to $55 from $45 at Evercore ISI
PremiumThe FlyEdgewise Therapeutics price target raised to $55 from $45 at Evercore ISI
1M ago
Edgewise Therapeutics Sells Muscular Dystrophy Assets to Servier
Premium
Company Announcements
Edgewise Therapeutics Sells Muscular Dystrophy Assets to Servier
1M ago
Edgewise Therapeutics completes sale of sevasemten for up to $2.65B
Premium
The Fly
Edgewise Therapeutics completes sale of sevasemten for up to $2.65B
1M ago
Edgewise Therapeutics price target raised to $32 from $20 at Goldman Sachs
PremiumThe FlyEdgewise Therapeutics price target raised to $32 from $20 at Goldman Sachs
2M ago
Edgewise Therapeutics price target raised to $52 from $50 at Leerink
Premium
The Fly
Edgewise Therapeutics price target raised to $52 from $50 at Leerink
2M ago
Buy Rating Reiterated on Edgewise Therapeutics as Strong EDG-7500 Data and Asset Sale Support Cardiovascular Pipeline; $45 Price Target Unchanged
Premium
Ratings
Buy Rating Reiterated on Edgewise Therapeutics as Strong EDG-7500 Data and Asset Sale Support Cardiovascular Pipeline; $45 Price Target Unchanged
2M ago
Edgewise Therapeutics Shareholders Back Board and Governance
PremiumCompany AnnouncementsEdgewise Therapeutics Shareholders Back Board and Governance
3M ago
Edgewise Therapeutics price target raised to $53 from $45 at JPMorgan
Premium
The Fly
Edgewise Therapeutics price target raised to $53 from $45 at JPMorgan
3M ago
Acting FDA head vows to block political interference, Endpoint News says
Premium
The Fly
Acting FDA head vows to block political interference, Endpoint News says
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100